(Q42855681)

8 November 2017

0 references

Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules (English)

1 reference

metastatic renal cell carcinoma

8 November 2017

1 reference

1 reference

1 reference

Sumanta Kumar Pal

1

1 reference

8 November 2017

Robert A Figlin

series ordinal

2

1 reference

8 November 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Expert Opinion on Biological Therapy

8 November 2017

published in

1 reference

8 November 2017

volume

10

1 reference

8 November 2017

issue

11

1 reference

8 November 2017

page(s)

1517-1520

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.522904

10.1517/14712598.2010.522904

21 January 2018

Identifiers

DOI

1 reference

8 November 2017

1 reference